@article {edalatifard2002808，作者= {edalatifard，maryam和akhtari，maryam和salehi，salehi，mohammadreza和naderi，zohre and jamshidi，jamshidi，ahmadreza，ahmadreza and Mostafaei，and Mostafaei，shayan and Najafizadeh，shayan and Najafizadeh and noosh and noosh and noosh and anham and anham and anham and erham and estham and ash anham and estham and estham and estham and estham和, Besharat and Kazemzadeh, Hossein and Mahmoodi Aliabadi, Maedeh and Ghazanfari, Tooba and Sattarian, Mohammadreza and Ebrahimi Louyeh, Hourvash and Raeeskarami, Seyed Reza and Jamalimoghadamsiahkali, Saeidreza and Khajavirad, Nasim and Mahmoudi, Mahdi and Rostamian, Abdolrahman}, title = {静脉注射甲基强龙脉冲作为住院严重的Covid-19患者的治疗：来自随机对照临床试验的结果}，体积= {56}，数字= {6}，Elocation-id = {2002808}，年= {2020}，doi {2020}，doi= {10.1183/13993003.02808-2020}，出版商= {欧洲呼吸社会}，188bet官网地址摘要= {简介尚无确定的严重covid-19治疗剂。有人提出，作为一种免疫抑制治疗，甲基强酮可以减少COVID-19患者呼吸系统的炎症。方法我们进行了一项单盲，随机对照临床试验，涉及早期肺部肺部确认的COVID患者的严重住院患者伊朗疾病的阶段。通过块随机化方法将患者以1：1的比率随机分配，以通过甲基促旋龙脉冲接受标准护理（静脉注射，250 mg {\ TextperiodeDcentered}第1天或单独使用标准护理。研究终点是临床改善或死亡的时间，以先到者为准。在意向治疗（ITT）人群中进行了初级和安全分析。从2020年4月20日至2020年6月20日，68名合格患者进行了随机分析（每组34例）。在标准护理组中，有6例患者在治疗前，主治医生接受了皮质类固醇，并从整体分析中排除了皮质类固醇。在甲基丙酮组中，改善患者的百分比高于标准护理组（94.1 \％对57.1 \％\％），并且甲基丙酮基组的死亡率明显低（5.9 \％\％v vers 42.9 \％; p \ <0.001; p \ <0.001; p \ <0.001;）。 We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p\<0.001; hazard ratio 0.293, 95\% CI 0.154{\textendash}0.556). Two patients (5.8\%) in the methylprednisolone group and two patients (7.1\%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.Conclusions Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.This study showed that methylprednisolone pulse administration at the beginning of the early pulmonary phase of illness decreased the mortality rate and improved pulmonary involvement, oxygen saturation and inflammatory markers in COVID-19 patients https://bit.ly/3hik4JB}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/56/6/2002808}, eprint = {//www.qdcxjkg.com/content/56/6/2002808.full.pdf}, journal = {European Respiratory Journal} }